Tuberculosis. Tuberculosis of lung,confirmed by sputum microscopy with or without culture
Conditions
Interventions
Intervention 1: In this clinical trial study, in 32 patients as case group, along with routine anti-tuberculosis treatment for 6 months, vitamin D 450,000 IU intramuscularly in a single dose at the be
Treatment - Drugs
In this clinical trial study, in 32 patients as case group, along with routine anti-tuberculosis treatment for 6 months, vitamin D 450,000 IU intramuscularly in a single dose at the beginning of treat
In this clinical trial study, in 32 patients as control group, along with routine anti-tuberculosis treatment for 6 months, placebo (Normal Saline) intramuscularly in a single dose at the beginning of
Sponsors
Arak University of Medical Sciences
Eligibility
Sex/Gender
All
Age
15 Years to No maximum
Inclusion criteria
Inclusion criteria: Inclusion criteria: patients with smear positive pulmonary tuberculosis; younger than 15 years for entry into the study; obtain informed consent Exclusion criteria: Patients who have medical complications during the follow-up study; patients who need to change during the study medication are routine tuberculosis; Patients who are suffering from systemic disease or other debilitating (Such as chronic liver disease, kidney disease, HIV, Malignancy etc); patients who have recently used of vitamin D in any other reason; Patients taking vitamin D in the past have suffered side effects or drug allergy; Pregnancy; in patients who taking of vitamin D is prohibited
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Erythrocyte Sedimentation Rate. Timepoint: Weeks of 2,4,6,8. Method of measurement: With westergren method - millimeters per first hour.;C-Reactive Protein. Timepoint: Weeks of 2,4,6,8. Method of measurement: Latex method - 1+ to 4+.;Complete Blood Count. Timepoint: Weeks of 2,4,6,8. Method of measurement: Measurment of Hgb and WBC.;Improvement of patient's symptoms. Timepoint: Weeks of 2,4,6,8. Method of measurement: Check list. | — |
Secondary
| Measure | Time frame |
|---|---|
| Improved quality of life. Timepoint: Day 0 and day 30 of treatment. Method of measurement: SF-12 questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAliasghar Farazi
Arak University of Medical Sciences
Outcome results
None listed